The nation of Zimbabwe has rejected a substantial US healthcare agreement worth $367m (272 million pounds) spanning five years due to Washington's demand for sensitive biological samples.
This move became public after a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "skewed".
An official representative later clarified that the United States was seeking genetic material for scientific study and commercial gain while was unwilling to guarantee the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for continued dialogue to secure a agreement acceptable to all parties so the nation's critical HIV programme can continue.
Broader Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court blocked a related health funding agreement following concerns were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and responsibility.
According to statements, Sixteen African countries have so far agreed to similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, with no equivalent guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its push of bilateral deals were disrupting systems already set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how future co-operation could be designed in a manner that respects the independence and interests of each country."
Medical Community Response
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks need to persist given that much of the nation's HIV programmes depended on international support.
"In cases where specific concerns exist, such as those relating to data governance or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
This impasse underscores the complex debate between receiving crucial international aid and safeguarding national sovereignty in an increasingly data-driven world.